Clinical guidelines recommend extended treatment with dual antiplatelet therapy (DAPT) with ticagrelor 60 mg (twice daily) beyond 12 months in high-risk patients with a history of myocardial infarction (MI) who have previously tolerated DAPT and are not at heightened bleeding risk. However, evidence on patterns of use and associated clinical outcomes in routine clinical practice is limited.

中文翻译：

---

替格瑞洛 60 mg 对既往心肌梗死患者的延长双重抗血小板治疗：ALETHEIA 的设计，一项多国观察性研究

临床指南建议，对既往耐受 DAPT 且出血风险不高的有心肌梗塞 (MI) 病史的高危患者，使用替格瑞洛 60 mg（每天两次）的双重抗血小板治疗 (DAPT) 延长治疗 12 个月以上。然而，关于常规临床实践中使用模式和相关临床结果的证据有限。